
    
      The trial is a phase II, open label, non-randomized, prospective multicenter trial to assess
      the pharmacokinetics and long term plasma exposure of the following antiretrovirals:
      atazanavir when combined to ritonavir and the tenofovir/emtricitabine fixed-dose combination.
      All drugs will be delivered in MEMS electronic device to monitor dosing history.
    
  